Analysts Issue Forecasts for Humana Inc.’s Q3 2024 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Equities research analysts at Leerink Partnrs reduced their Q3 2024 earnings per share estimates for Humana in a report issued on Wednesday, April 24th. Leerink Partnrs analyst W. Mayo now anticipates that the insurance provider will post earnings of $4.08 per share for the quarter, down from their prior estimate of $4.38. The consensus estimate for Humana’s current full-year earnings is $16.08 per share. Leerink Partnrs also issued estimates for Humana’s Q4 2024 earnings at ($1.86) EPS, Q1 2025 earnings at $8.76 EPS, Q3 2025 earnings at $5.75 EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at $22.16 EPS.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. Humana’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.38 EPS.

A number of other research firms have also recently weighed in on HUM. TheStreet cut shares of Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. The Goldman Sachs Group dropped their target price on shares of Humana from $450.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. Jefferies Financial Group reduced their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research report on Monday, April 22nd. Truist Financial reaffirmed a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Finally, Raymond James assumed coverage on Humana in a research report on Friday, March 22nd. They set a “market perform” rating on the stock. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $424.50.

Humana Trading Down 1.8 %

Shares of HUM stock opened at $305.90 on Monday. Humana has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The business’s fifty day moving average price is $327.77 and its 200 day moving average price is $393.91. The firm has a market capitalization of $36.86 billion, a PE ratio of 19.05, a P/E/G ratio of 1.79 and a beta of 0.45.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC increased its holdings in shares of Humana by 129.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,140 shares of the insurance provider’s stock worth $555,000 after buying an additional 644 shares during the last quarter. Plimoth Trust Co. LLC increased its stake in Humana by 19.9% during the third quarter. Plimoth Trust Co. LLC now owns 790 shares of the insurance provider’s stock worth $384,000 after acquiring an additional 131 shares during the last quarter. PDS Planning Inc raised its holdings in shares of Humana by 4.1% in the 3rd quarter. PDS Planning Inc now owns 609 shares of the insurance provider’s stock worth $296,000 after purchasing an additional 24 shares during the period. Copeland Capital Management LLC lifted its stake in shares of Humana by 20.3% in the 3rd quarter. Copeland Capital Management LLC now owns 635 shares of the insurance provider’s stock valued at $309,000 after purchasing an additional 107 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in shares of Humana by 0.5% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 26,813 shares of the insurance provider’s stock worth $13,045,000 after purchasing an additional 125 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is presently 22.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.